D. Schadendorf

Skin cancers are the most frequent cancers in fair-skinned populations, but we can prevent them.

A. Lallas, V. del Marmol, B. Volkmer, 2024, European journal of cancer.

Association of antibiotic treatment with survival outcomes in treatment-naïve melanoma patients receiving immune checkpoint blockade.

K. Kähler, C. M. Thielmann, Emmanouil Gratsias, 2024, European journal of cancer.

Anti-PD-(L)1 plus BRAF/MEK inhibitors (triplet therapy) after failure of immune checkpoint inhibition and targeted therapy in patients with advanced melanoma.

A. Forschner, A. Menzies, P. Grover, 2024, European journal of cancer.

Anti-PD-1 alone or in combination with anti-CTLA-4 for advanced melanoma patients with liver metastases.

I. Pires da Silva, Jorja Braden, P. Serra-Bellver, 2024, European journal of cancer.

Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): long-term, health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial.

C. Coens, A. van den Eertwegh, V. Atkinson, 2024, The Lancet. Oncology.

COLUMBUS 7-year update: A randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF V600E/K-mutant melanoma.

P. Ascierto, I. Krajsová, A. Arance, 2024, European journal of cancer.

Real-World efficiency of pembrolizumab in metastatic melanoma patients following adjuvant anti-PD1 treatment

F. Meier, E. Ellebaek, L. Kandolf, 2024, EJC Skin Cancer.

High response rate with extended dosing of cemiplimab in advanced cutaneous squamous cell carcinoma

I. Lowy, N. Basset-Seguin, C. Schmults, 2024, Journal for ImmunoTherapy of Cancer.